查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771589

Vifugart（Efgartigimod）市场规模、份额、趋势分析报告：按适应症、给药途径、地区、细分市场预测，2025-2030 年

Vyvgart (Efgartigimod) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Wifgart（Efgartigimod）市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球 Vifugart（efgaltigimod）市场规模预计到 2030 年将达到 55 亿美元，2025 年至 2030 年的复合年增长率为 13.6%。

efgartigimod 是由 argenx SE 开发的First-in-Class新生儿 Fc 受体 (FcRn) 拮抗剂，随着其治疗领域在多种自体免疫疾病中的扩展，其市场正在快速发展。 efgartigimod 最初核准用于治疗重症肌无力 (gMG)，随后又核准用于治疗原发性血小板减少性疾病(ITP) 和慢性脱髓鞘多发性神经炎(CIDP)，目前正在进一步开髮用于治疗 FcRn 相关的免疫疾病。

Wifgart 的临床价值在于其独特的作用机制，透过抑制 FcRn 循环途径来降低致病性 IgG 自体抗体。这种标靶疗法可以选择性地调节免疫功能，而不会广泛抑制免疫系统，并且安全性良好。该疗法已在慢性抗体依赖性疾病（例如 gMG 和 CIDP）中显示出强大的疗效，并且越来越多的证据支持其在其他自体免疫疾病中的应用。

儘管成人患者仍然是最大的治疗人群，尤其是在治疗诸如鉅细胞病毒性肌炎（gMG）等已确定的适应症方面，但儿童患者的治疗潜力日益增长，尤其是在慢性自体免疫神经病变和血液系统疾病方面。对年轻患者进行早期疗育，可能透过减缓病情进展和减少对广谱免疫抑制剂的依赖，带来长期益处。

专业药局在Wifgart的经销模式中占据核心地位，尤其对于需要精准协调和病患支援的输液和皮下製剂而言。医院药局在管理诱导用药和复杂病例方面仍然是至关重要的合作伙伴，尤其对于新诊断和严重患者而言。专业销售管道透过个人化照护方案、输液计画和远端患者协助，持续提升患者的可近性和依从性。

2025年4月，FDA核准了Hyfudura的预填充式注射器製剂，用于gMG和CIDP患者皮下注射自我给药，可在30秒内完成皮下给药，显着提高治疗灵活性和依从性。

此外，2025年4月，EMA人用药品委员会（CHMP）发表了积极意见，建议核准VYVGART皮下注射剂在欧洲用于治疗CIDP，为该地区30多年来首个CIDP标靶治疗的核准奠定了基础。

2024年11月，继ADHERE试验取得正面结果后，Hyfudura复合皮下注射液在中国核准用于治疗CIDP，进一步扩大了Argenx的全球影响力，巩固了其在神经肌肉市场的地位。

随着全球需求的成长，确保产品供应仍是 Argenx 的策略重点。对供应链扩充性和以患者为中心的数位平台的投资增强了护理的连续性，从而增强了医疗服务提供者和患者的权能。这些工具对于长期復发性自体免疫疾病的管理尤其重要，因为护理的无缝过渡和主动的疾病监测对疗效有重大影响。

Wifcart 的成功凸显了向精准免疫疗法的模式转移，这种疗法可以调节特定的疾病通路，并产生持久的标靶效应。随着我们对自体免疫疾病的认识和诊断能力不断提高，Wifcart 仍然是 FcRn 抑制剂领域的领先选择，有望带来更佳的疗效，并重塑一系列免疫介导疾病的治疗标准。

Wifgart（Efgartigimod）市场报告重点

  • 从适应症来看，重症肌无力 (gMG) 仍将是 2024 年 Vifugart (efgartigimod) 市场的主要适应症，由于该药物血清阳性患者比例高，且透过 FcRn 抑制标靶作用机制，其将占据最大市场份额。其优异的临床表现、良好的安全性以及最新的治疗指南正在加速其在主要市场的推广。
  • 根据给药途径，静脉输液将在 2024 年占据给药途径领域的主导地位。然而，皮下製剂正在迅速转变，尤其是最近核准的预填充式注射器，这种注射器允许自我给药并为患者提供更大的便利。
  • 受自体免疫疾病高诊断率和治疗率、优惠的报销政策以及强大的专业药房基础设施的推动，北美在 2024 年引领了 WiFgart 市场。该地区也受益于活性化和创新免疫疗法的早期采用。
  • Algenx SE 继续引领全球 Vifugart (efgaltigimod) 市场，凭藉其强大的研发开发平臺、不断增长的国际核准以及与中国再鼎医药等区域性企业的战略伙伴关係。公司专注于供应链弹性、患者援助项目和基于平台的开发，这将支持其在多个适应症和地区的长期成长。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章 Wifgart（Efgartigimod）市场的变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
  • 管道分析
  • 专利到期分析
  • 定价分析

第四章 VIFGART（EFGARTIGIMOD）市场：适应症业务分析

  • 2024年及2030年指示市场占有率
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（2018-2030 年）
  • 慢性脱髓鞘多发性神经炎（CIDP）
  • 全身性重症肌无力（gMG）
  • 其他的

第五章 VIFGART（EFGARTIGIMOD）市场路线管理业务分析

  • 2024 年及 2030 年给药途径市场占有率
  • 给药途径细分仪表板
  • 按管理路线分類的市场规模、预测和趋势分析（2018-2030 年）
  • 静脉输液
  • 皮下注射
  • 预填充式注射器

第六章 Wifgart（Efgartigimod）市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模与预测趋势分析：
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Argenx SE

第 8 章 结论

Product Code: GVR-4-68040-618-7

Vyvgart (Efgartigimod) Market Growth & Trends:

The global Vyvgart (Efgartigimod) market size is anticipated to reach USD 5.50 billion by 2030 and is projected to grow at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Vyvgart (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) antagonist developed by argenx SE, is rapidly evolving as its therapeutic footprint expands across multiple autoimmune indications. Initially approved for generalized myasthenia gravis (gMG), Vyvgart has since entered the treatment landscapes for Primary Immune Thrombocytopenia (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with ongoing exploration into additional FcRn-related immune disorders.

Vyvgart's clinical value lies in its unique mechanism of action that reduces pathogenic IgG autoantibodies by inhibiting the FcRn recycling pathway. This targeted approach allows for selective immunomodulation without broadly suppressing the immune system, offering a favorable safety profile. The treatment has demonstrated robust efficacy in chronic, antibody-driven conditions like gMG and CIDP, with growing evidence supporting its use across other autoimmune indications.

While adult patients represent the largest treated population, especially in well-established indications such as gMG, the therapeutic potential for pediatric use is gaining momentum, particularly in chronic autoimmune neuropathies and hematologic disorders. Early intervention in younger patients could offer long-term benefits by curbing disease progression and reducing reliance on broad-spectrum immunosuppressants.

Specialty pharmacies are at the forefront of Vyvgart's distribution model, particularly due to the drug's infusion-based and subcutaneous formulations, which require precise coordination and patient support. Hospital pharmacies continue to be key partners in managing induction and complex cases, especially for newly diagnosed or severely affected patients. Increasingly, specialty distribution channels are enhancing access and adherence through personalized care programs, infusion scheduling, and remote patient engagement.

In April 2025, the FDA approved a prefilled syringe formulation of VYVGART Hytrulo for self-administration in patients with gMG and CIDP. This enables subcutaneous delivery in under 30 seconds, significantly improving treatment flexibility and adherence.

Also in April 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of VYVGART subcutaneous injection for CIDP in Europe, setting the stage for the first targeted CIDP therapy approval in the region in over three decades.

In November 2024, VYVGART Hytrulo received regulatory approval in China for treating CIDP, following strong results from the ADHERE trial. This further expanded its global footprint and solidified Argenx's position in neuromuscular markets.

As demand grows globally, ensuring consistent product availability remains a strategic priority for argenx. Investments in supply chain scalability and patient-centered digital platforms are reinforcing treatment continuity and empowering both providers and patients. These tools are especially critical in managing long-term, relapsing autoimmune conditions, where seamless care transitions and proactive disease monitoring can significantly impact outcomes.

The success of Vyvgart underscores a broader paradigm shift toward precision immunotherapies that modulate specific disease pathways with durable, targeted effects. As awareness and diagnostic capabilities for autoimmune diseases continue to improve, Vyvgart is poised to remain a leading option in the FcRn inhibition class, driving better outcomes and reshaping the standard of care across a range of debilitating immune-mediated disorders.

Vyvgart (Efgartigimod) Market Report Highlights:

  • Based on indication, Generalized Myasthenia Gravis (gMG) remained the leading indication in the Vyvgart (Efgartigimod) market in 2024, accounting for the largest share due to the high prevalence of antibody-positive patients and the drug's targeted mechanism of action through FcRn inhibition. Strong clinical outcomes, favorable safety profile, and updates to treatment guidelines have accelerated adoption across major markets.
  • Based on route of administration, Intravenous (IV) Infusion dominated the route of administration segment in 2024, primarily due to its early commercial availability and widespread adoption in hospital settings for induction therapy. However, the market is witnessing a rapid shift towards subcutaneous formulations, particularly the recently approved prefilled syringe, which offers self-administration and greater patient convenience.
  • North America led the Vyvgart market in 2024, supported by high diagnosis and treatment rates of autoimmune diseases, favorable reimbursement policies, and a robust specialty pharmacy infrastructure. The region also benefits from increasing clinical trial activity and early adoption of innovative immunotherapies.
  • Argenx SE continued to lead the Vyvgart (Efgartigimod) market globally, leveraging its robust R&D pipeline, expanding international approvals, and strategic partnerships with regional players like Zai Lab in China. The company's focus on supply chain resilience, patient assistance programs, and platform-based development supports its long-term growth across multiple indications and geographies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Vyvgart (Efgartigimod) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Patent Expiry Analysis
  • 3.6. Pricing Analysis

Chapter 4. Vyvgart (Efgartigimod) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 4.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, 2018 - 2030 (USD Million)
  • 4.5. Generalized Myasthenia Gravis (gMG)
    • 4.5.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Vyvgart (Efgartigimod) Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Intravenous (IV) Infusion
    • 5.4.1. Intravenous (IV) Infusion Market, 2018 - 2030 (USD Million)
  • 5.5. Subcutaneous (SC) Injection
    • 5.5.1. Subcutaneous (SC) Injection Market, 2018 - 2030 (USD Million)
  • 5.6. Prefilled Syringes
    • 5.6.1. Prefilled Syringe Market, 2018 - 2030 (USD Million)

Chapter 6. Vyvgart (Efgartigimod) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Vyvgart (Efgartigimod) Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Vyvgart (Efgartigimod) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Argenx SE
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

Chapter 8. Conclusion

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Vyvgart (Efgartigimod) market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 5. Global Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6. North America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 7. North America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 8. North America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9. U.S. Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 10. U.S. Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11. Canada Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 12. Canada Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13. Mexico Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 14. Mexico Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15. Europe Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 17. Europe Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18. UK Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 19. UK Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Germany Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 21. Germany Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22. France Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 23. France Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Italy Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 25. Italy Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26. Spain Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 27. Spain Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28. Norway Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 29. Norway Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30. Denmark Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 31. Denmark Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32. Sweden Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 33. Sweden Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Japan Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 38. Japan Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39. China Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 40. China Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. India Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 42. India Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43. Australia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 44. Australia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. South Korea Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 46. South Korea Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47. Thailand Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 48. Thailand Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Latin America Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 51. Latin America Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52. Brazil Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 53. Brazil Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54. Argentina Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 55. Argentina Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Vyvgart (Efgartigimod) market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59. South Africa Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 60. South Africa Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63. UAE Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 64. UAE Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Vyvgart (Efgartigimod) market, by indication, 2018 - 2030 (USD Million)
  • Table 66. Kuwait Vyvgart (Efgartigimod) market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Vyvgart (Efgartigimod) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and route of administration outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Vyvgart (Efgartigimod) market dynamics
  • Fig. 12 Vyvgart (Efgartigimod) market: Porter's five forces analysis
  • Fig. 13 Vyvgart (Efgartigimod) market: PESTLE analysis
  • Fig. 14 Indication market, 2018 - 2030 (USD Million)
  • Fig. 15 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, 2018 - 2030 (USD Million)
  • Fig. 16 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Route of Administration market, 2018 - 2030 (USD Million)
  • Fig. 19 Intravenous (IV) Infusion market, 2018 - 2030 (USD Million)
  • Fig. 20 Subcutaneous (SC) Injection market, 2018 - 2030 (USD Million)
  • Fig. 21 Prefilled Syringe market, 2018 - 2030 (USD Million)
  • Fig. 22 Vyvgart (Efgartigimod) market revenue, by region
  • Fig. 23 Regional marketplace: Key takeaways
  • Fig. 24 North America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. country dynamics
  • Fig. 26 U.S. Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 27 Canada country dynamics
  • Fig. 28 Canada Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico country dynamics
  • Fig. 30 Mexico Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 32 UK country dynamics
  • Fig. 33 UK Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany country dynamics
  • Fig. 35 Germany Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 36 France country dynamics
  • Fig. 37 France Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 38 Italy country dynamics
  • Fig. 39 Italy Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain country dynamics
  • Fig. 41 Spain Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 42 Norway country dynamics
  • Fig. 43 Norway Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden country dynamics
  • Fig. 45 Sweden Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark country dynamics
  • Fig. 47 Denmark Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 49 Japan country dynamics
  • Fig. 50 Japan Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 51 China country dynamics
  • Fig. 52 China Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 53 India country dynamics
  • Fig. 54 India Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia country dynamics
  • Fig. 56 Australia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea country dynamics
  • Fig. 58 South Korea Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand country dynamics
  • Fig. 60 Thailand Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil country dynamics
  • Fig. 63 Brazil Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina country dynamics
  • Fig. 65 Argentina Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa country dynamics
  • Fig. 68 South Africa Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 69 Saudi Arabia country dynamics
  • Fig. 70 Saudi Arabia Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 71 UAE country dynamics
  • Fig. 72 UAE Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 73 Kuwait country dynamics
  • Fig. 74 Kuwait Vyvgart (Efgartigimod) market, 2018 - 2030 (USD Million)
  • Fig. 75 Company categorization
  • Fig. 76 Company market position analysis
  • Fig. 77 Strategic framework